<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>state-occupancy model &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/state-occupancy-model/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 01:37:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>state-occupancy model &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Venetoclax Combo Extends Life in Bulgarian AML Patients but at a Steep Price, Real-World Model Finds</title>
		<link>https://bioengineer.org/venetoclax-combo-extends-life-in-bulgarian-aml-patients-but-at-a-steep-price-real-world-model-finds/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 01:37:23 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[acute myeloid leukemia]]></category>
		<category><![CDATA[azacitidine]]></category>
		<category><![CDATA[Bulgaria]]></category>
		<category><![CDATA[cost-effectiveness]]></category>
		<category><![CDATA[Cost-utility analysis]]></category>
		<category><![CDATA[health economics]]></category>
		<category><![CDATA[National Health Insurance Fund]]></category>
		<category><![CDATA[pharmacoeconomics]]></category>
		<category><![CDATA[QALY]]></category>
		<category><![CDATA[Real-world data]]></category>
		<category><![CDATA[state-occupancy model]]></category>
		<category><![CDATA[Venetoclax]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=424382</guid>

					<description><![CDATA[A Bulgarian real-world economic model finds that venetoclax plus azacitidine improves survival and quality of life in older AML patients unfit for intensive chemotherapy, but at a cost-effectiveness ratio far exceeding national thresholds.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">424382</post-id>	</item>
	</channel>
</rss>
